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and 59.1% received a lower dose at Month 6. At Month 
6, 80.8/57.7/17.3% of patients had a physician-determined 
clinical improvement of ≥20/≥50/≥80%, respectively. Six-
teen patients had a SLE Disease Activity Index-2K score 
at both baseline and Month 6, with a mean improvement 
of 2.6 ± 5.3 from 8.1 ± 3.2 at baseline. No formal disease 
assessment tool was utilized for 42.3% of study patients at 
baseline. This study provides the first real-world insights 
into belimumab use in Canada. It demonstrates signifi-
cant reduction or discontinuation of glucocorticoid dose in 
70.5% of patients and clinically significant improvement 
following 6  months’ belimumab therapy. The high num-
ber of patients with no formal disease activity assessments 
highlights a key care gap in SLE treatment in the real-world 
setting.
Keywords Lupus erythematosus, systemic · B-cell 
activating factor · Observational study · Glucocorticoids · 
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Introduction/objectives
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease that affects approximately 31.9–51.0 
per 100,000 persons in Canada, depending on the case 
definition used [1]. Standard therapies for SLE include 
glucocorticoids, antimalarial agents, non-steroidal anti-
inflammatory drugs (NSAIDs), cyclophosphamide, and 
immunosuppressive/immunomodulatory agents [2–6]. 
Despite improvements in medical care leading to improved 
survival of patients with SLE in recent decades [7], long-
term morbidity can adversely affect patients’ quality of life 
and their ability to work, resulting in substantial direct and 
indirect costs.
Abstract To describe the characteristics of patients 
receiving belimumab, overall patterns of systemic lupus 
erythematosus (SLE) care, clinical outcomes, and changes 
in glucocorticoid dose following 6  months of therapy 
with belimumab, and healthcare resource utilization in 
belimumab users in Canadian clinical practice settings. Ret-
rospective multicenter medical chart review study of adult 
patients with SLE who were prescribed belimumab as part 
of usual care and who received ≥8 infusions or 6  months 
of treatment. Primary endpoints included physician- 
determined overall clinical improvement from baseline, 
glucocorticoid use, and physician-determined SLE disease 
severity at Month 6. In total, 52 patients were included 
in the study. At belimumab initiation, 5.8/76.9/17.3% of 
patients had mild/moderate/severe SLE, respectively. Oral 
glucocorticoids were discontinued in 11.4% of patients 
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Belimumab (Benlysta™) is a B-lymphocyte stimula-
tor (BLyS)-specific inhibitor that blocks the binding of 
soluble BLyS, a B-cell survival factor, to its receptors on 
B cells [8]. Belimumab was approved in Canada in 2011 
and is indicated in addition to standard therapy for reducing 
disease activity in adult patients with active, autoantibody-
positive SLE [9]. Two pivotal Phase 3 randomized, double-
blind, placebo-controlled trials (BLISS-52 and BLISS-76), 
conducted in adults with SLE, demonstrated superiority of 
belimumab over placebo plus standard of care in the pri-
mary efficacy analysis of response rate, measured by the 
SLE responder index (SRI) at Week 52. Reductions in dis-
ease activity and severe flares were also observed [10, 11].
While the clinical efficacy of belimumab has been 
demonstrated in randomized controlled trials, utilization 
patterns and clinical benefit in real-world clinical prac-
tice have not been studied in Canada. The OBSErve stud-
ies (evaluation Of use of Belimumab in clinical practice 
SEttings) are observational studies designed to describe the 
overall patterns of SLE care and clinical outcomes follow-
ing belimumab therapy in a real-world setting in different 
countries. The first of the OBSErve studies to report was 
the OBSErve US study (GSK study 117295), conducted 
in the USA, which investigated the clinical effectiveness, 
changes in laboratory parameters and healthcare resource 
utilization associated with belimumab plus standard of care 
in a cohort of patients with SLE over 24 months in clinical 
practice [12]. Here we present the results of the OBSErve 
Canada study (GSK Study 117300), which aimed to pro-
vide real-world insights on the characteristics of patients 
receiving belimumab in clinical practices in Canada, as 
well as to describe overall patterns of SLE care, clinical 
outcomes, including changes in glucocorticoid dose, fol-




This was a multicenter, retrospective, medical chart review 
study conducted in Canada. The study period included 
the 6-month treatment history period prior to the index 
date (belimumab initiation date; baseline) and a 6-month 
follow-up period after the index date.
Rheumatologists, who managed/treated ≥10 patients 
with SLE, had ≥5 years of experience in treating SLE and 
had ≥2 patients currently receiving belimumab (of whom 
≥1 patient had received ≥8 infusions) were recruited to 
participate in the study. Participating physicians were 
responsible for patient selection and enrollment, chart 
data abstraction and data validation. Data collection 
occurred by physician abstraction of patient medical 
chart data onto the paper-based physician practice profile 
form (PPPF) and study case report forms (CRFs). CRFs 
captured patient demographics, comorbidities, SLE dis-
ease characteristics including disease course and disease 
activity assessment, prior SLE treatments, belimumab 
initiation profile including reason for initiation, concomi-
tant medications and healthcare resource use. All patient 
data were anonymized. While this study was not designed 
to collect data relating to safety of belimumab, nor was 
this an objective, available data pertaining to adverse 
events (AEs) were summarized and AEs that the physi-
cian deemed belimumab-related were reported to the 
study sponsor.
Central ethics approval for the study was obtained 
from the Veritas independent review board (IRB; pro-
ject reference ‘Evaluation of Use of Belimumab in Clini-
cal Practice Settings [OBSErve]’). Institutional research 
ethics board approvals were also obtained from the 
University Health Network Research Ethics Board (14-
7641-BE), Hamilton Integrated Research Ethics Board 
(13-743-C), and McGill University Health Centre Genet-
ics/Population Research Investigator Initiated Studies 
Research Ethics Board (13-097 GEN). As patient data 
were anonymized, a waiver of informed consent for study 
patients was granted by the Veritas IRB.
Patient population
Physicians enrolled all patients from their practice who 
fulfilled the following inclusion criteria: adults aged 
≥18  years with a diagnosis of SLE based on the physi-
cian’s judgement, who had received, as part of usual-care, 
≥8 belimumab infusions (6  months of continuous treat-
ment); reason for belimumab initiation could be identi-
fied; ≥6  months of medical history prior to belimumab 
initiation was documented with the participating study 
physician. Patients enrolled in any other SLE-related 
clinical trial were excluded.
Primary study endpoints
The primary study endpoints included: physician- 
determined SLE disease severity (mild, moderate, 
severe); patterns of SLE care among belimumab users in 
clinical practice in Canada; SLE clinical outcome meas-
ures at Month 6, as measured by physician-determined 
overall clinical status compared with baseline [worse, no 





Other study endpoints included measures of disease activity 
routinely used by physicians, such as the physician global 
assessment (PhGA), patient global assessment (PtGA), the 
Systemic Lupus Erythematosus Disease Activity Index 
2000 (SLEDAI-2K) or its derivation, the British Isles 
Lupus Assessment Group (BILAG) score, and the Fatigue 
Severity Scale. The PtGA score is reported on a scale of 0 
(no disease activity)−100 (high disease activity). Change in 
PtGA was calculated for patients who had a score recorded 
on the CRF at baseline and Month 6.
Statistical analyses
Due to the largely descriptive nature of the study, no for-
mal sample size calculations were undertaken to determine 
the number of physicians or patients to be included in the 
study. The study sample size was based solely on the num-
ber of physicians and patients who met the inclusion crite-
ria at baseline. Descriptive statistics and univariate analy-
ses were conducted where appropriate.
Results
Physician characteristics
Seven rheumatologists (four hospital-based, three 
community-based) were recruited. The majority (n = 6) 
practiced in urban settings. Four physicians were individual 
practitioners and three were members of a group practice. 
At the time of baseline data collection, physicians esti-
mated that in total they were currently treating or manag-
ing a mean of 1814 ± 684.2 patients, of whom 176 ± 113.7 
patients had SLE. Physicians reported a mean of 9 ± 9.3 
patients currently receiving belimumab.
Four rheumatologists (57.1%) reported routinely using 
the PhGA and the PtGA, and two physicians (28.6%) each 
also reported routinely measuring SLEDAI-2K, BILAG 
score, and the Fatigue Severity Scale. Three rheumatolo-
gists (42.9%) reported that they did not routinely use any 
disease activity instrument.
Patient characteristics
A total of 52 patients were included in the study. 
Patients were predominantly female (94.2%) and largely 
Caucasian (65.4%), followed by African origin (15.4%), 
Asian (11.5%), Hispanic (5.8%), and West Indian (1.9%). 
The mean (SD) age of the patients was 46.5 (10.8) years 
(Table 1). Patients had a mean of 2.8 ± 2.2 comorbidities, 
the most common of which were hypertension (44.2%), 
hyperlipidemia (23.1%), depression (15.4%), and fibro-
myalgia (13.5%). Approximately 40% of patients were 
employed (34.6% full time and 5.8% part time) and 28.8, 
13.5, and 5.8% were reported as having disabled, unem-
ployed, and retired employment status, respectively. The 
most frequently cited reasons for starting belimumab 
therapy were: previous treatment regimen was not effec-
tive (69.2%); aim to decrease use or dose of glucocorti-
coids (67.3%); worsening patient condition (50.0%); and 
previous treatment regimen not well tolerated (17.3%).
SLE disease characteristics
More than half of the patients (53.8%) had been diag-
nosed with SLE for more than 10  years (Table  1). The 
most common clinical manifestations were musculo-
skeletal (71.2%), mucocutaneous (55.8%), immuno-
logic (30.8%), or constitutional (fatigue) (28.8%). The 
most frequently reported specific SLE manifestations 
were arthritis (69.2%), rashes (46.2%), low complement 
(26.9%), and increased anti-double-stranded DNA (anti-
dsDNA) antibody levels (21.2%). Other associated fea-
tures frequently reported were fatigue (28.8%) and alo-
pecia (21.2%). Physician-assessed SLE disease severity, 
at initial SLE diagnosis and at belimumab initiation, was 
reported as mild/moderate/severe in 5.8/51.9/42.3% and 
5.8/76.9/17.3% of patients, respectively. The majority 
(86.5%) of patients had ≥2 clinical SLE manifestations at 
belimumab initiation, with a mean of 3.1 ± 1.5 manifesta-
tions, ranging from 0.7 in patients with mild SLE to 3.2 
in those with moderate or severe SLE.
In the 6  months prior to belimumab initiation, all 
patients received immunosuppressants, often in com-
bination with oral glucocorticoids (96.2%), antimalari-
als (92.3%), and/or NSAIDs (55.8%). Combination SLE 
therapy continued to be common at baseline, with most 
patients receiving oral glucocorticoids (84.6%), anti-
malarials (76.9%), and/or immunosuppressants (73.1%) 
(Table  1). The most commonly prescribed immuno-
suppressants at baseline were mycophenolate mofetil 
(32.7%), azathioprine (21.2%), and methotrexate (17.3%).
The most frequently administered disease activity 
assessments at belimumab initiation among the study 
patient population were the PtGA (48.1%) and SLEDAI-
2K (or SELENA-SLEDAI) (32.7%). The fatigue sever-
ity scale was available for 30.8% of patients, PhGA for 
25.0%, and the health assessment questionnaire for 
25.0%. Formal disease assessment instruments were not 
utilized for 42.3% (22/52) of study patients, both at base-
line and Month 6.
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Table 1  Patient demographic and clinical characteristics
Anti-dsDNA anti-double-stranded DNA, C complement, NSAID non-steroidal anti-inflammatory drug, SD standard deviation, SLE systemic 
lupus erythematosus
a Immunosuppressants included mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, and mycophenolate sodium
Total patients with 
SLE (n = 52)
SLE disease severity
Mild (n = 3) Moderate (n = 40) Severe (n = 9)
Mean (SD) age (years) 46.5 (10.8) 43.3 (5.8) 46.8 (10.8) 46.7 (12.8)
Gender: female, n (%) 49 (94.2) 3 (100.0) 37 (92.5) 9 (100.0)
Race, n (%)
 Caucasian 34 (65.4) 2 (66.7) 24 (60.0) 8 (88.9)
 African origin 8 (15.4) 1 (33.3) 7 (17.5) –
 Asian 6 (11.5) – 6 (15.0) –
 Hispanic 3 (5.8) – 3 (7.5) –
 West Indian 1 (1.9) – – 1 (11.1)
Time since SLE diagnosis, n (%)
 0–5 years 12 (23.1) – 9 (22.5) 3 (33.3)
 6–10 years 12 (23.1) – 10 (25.0) 2 (22.2)
 >10 years 28 (53.8) 3 (100.0) 21 (52.5) 4 (44.4)
SLE disease severity at baseline, n (%)
 Mild 3 (5.8) 3 (100.0) – –
 Moderate 40 (76.9) – 40 (100.0) –
 Severe 9 (17.3) – – 9 (100.0)
SLE disease characteristics at baseline, n (%)
 High anti-dsDNA 22 (42.3) 2 (66.7) 16 (40.0) 4 (44.4)
 Low C4 20 (38.5) 2 (66.7) 15 (37.5) 3 (33.3)
 Low C3 17 (32.7) 3 (100.0) 12 (30.0) 2 (22.2)
 Leukopenia 9 (17.3) – 8 (20.0) 1 (11.1)
 Proteinuria 6 (11.5) – 5 (12.5) 1 (11.1)
 None 16 (30.8) – 12 (30.0) 4 (44.4)
Top 5 reasons for initiating belimumab, n (%)
 Previous treatment regimen ineffective 36 (69.2) 2 (66.7) 27 (67.5) 7 (77.8)
 Decrease use of glucocorticoids 35 (67.3) 3 (100.0) 26 (65.0) 6 (66.7)
 Worsening patient condition 26 (50.0) 1 (33.3) 18 (45.0) 7 (77.8)
 Previous treatment regimen not well tolerated 9 (17.3) – 8 (20.0) 1 (11.1)
 Patient request 2 (3.8) – 2 (5.0) –
Concomitant SLE medications, n (%)
 Oral glucocorticoids 44 (84.6) 3 (100.0) 32 (80.0) 9 (100.0)
 Antimalarials 40 (76.9) 3 (100.0) 32 (80.0) 5 (55.6)
 Immunosuppressanta 38 (73.1) 2 (66.7) 30 (75.0) 6 (66.7)
 NSAIDs 8 (15.4) – 6 (15.0) 2 (22.0)
Mean (SD) prednisone equivalent dose (mg/day) 13.6 (10.0) 13.3 (14.4) 13.3 (9.8) 14.7 (10.5)
Mean (SD) prednisone equivalent dose in patients with 
≥7.5 mg/day at index date (mg/day)





Following 6  months of belimumab treatment, 80.8, 57.7, 
and 17.3% of patients were observed by their physicians 
to have an overall clinical improvement of ≥20, ≥50, and 
≥80%, respectively (Table  2). Nine patients (17.3%) had 
<20% clinical improvement and one patient (1.9%) showed 
no improvement; no patients were reported to have had 
worsened disease. Similar trends in improvement were 
observed across the disease severity subgroups (Table 2).
Glucocorticoid use
Of the 44 patients receiving oral glucocorticoids at base-
line, five (11.4%) discontinued oral glucocorticoid ther-
apy after 6  months of belimumab therapy (Table  3). 
Among patients with SLE who were still receiving oral 
glucocorticoids after 6 months of belimumab therapy, the 
glucocorticoid dose was decreased for 59.1%, remained 
the same for 22.7%, and was increased for 6.8% of patients 
(Table 3). At Month 6, the mean glucocorticoid dose had 
decreased by 5.8  mg/day from baseline (Table  4). The 
mean reduction among patients with a baseline gluco-
corticoid dose ≥7.5  mg/day was 8.2 ± 9.8  mg/day after 
6  months of belimumab therapy (dose at belimumab ini-
tiation 17.8 ± 9.5  mg/day; dose following 6  months of 
belimumab 9.6 ± 6.0 mg/day).
Other concomitant medications
The percentage of patients receiving antimalarials at Month 
6 remained similar to baseline (78.8 vs. 76.9%), as did the 
percentage of patients receiving immunosuppressants (73.1 
vs. 69.2%). The percentage receiving NSAIDs remained 
the same (15.4%).
Table 2  Physician-determined 
clinical improvement from 
baseline at Month 6
SLE systemic lupus erythematosus
All patients (n = 52) Mild SLE (n = 3) Moderate 
SLE (n = 40)
Severe SLE (n = 9)
Worsened, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
No improvement, n (%) 1 (1.9) 0 (0) 1 (2.5) 0 (0)
<20% improvement, n (%) 9 (17.3) 0 (0) 7 (17.5) 2 (22.2)
≥20% improvement, n (%) 42 (80.8) 3 (100.0) 32 (80.0) 7 (77.8)
≥50% improvement, n (%) 30 (57.7) 3 (100.0) 23 (57.5) 4 (44.4)
≥80% improvement, n (%) 9 (17.3) 2 (66.7) 5 (12.5) 2 (22.2)
Table 3  Change in 
glucocorticoid use from 
baseline to Month 6
SLE systemic lupus erythematosus
All patients (n = 44) Mild SLE (n = 3) Moderate SLE 
(n = 32)
Severe SLE (n = 9)
Discontinued, n (%) 5 (11.4) 1 (33.3) 4 (12.5) 0 (0)
Decreased, n (%) 26 (59.1) 0 (0) 20 (62.5) 6 (66.7)
No change, n (%) 10 (22.7) 2 (66.7) 7 (21.9) 1 (11.1)
Increased, n (%) 3 (6.8) 0 (0) 1 (3.1) 2 (22.2)
Table 4  Change in oral glucocorticoid dose following 6 months of belimumab treatment
SD standard deviation, SLE systemic lupus erythematosus
Total patients 
with SLE (n = 52)
Mild SLE (n = 3) Moderate 
SLE (n = 40)
Severe SLE (n = 9)
Prescribed glucocorticoids at baseline (n) 44 3 32 9
 Mean (SD) glucocorticoid dose at belimumab initiation (mg/day) 13.6 (10.0) 13.3 (14.4) 13.3 (9.8) 14.7 (10.5)
Continued glucocorticoids at Month 6 (n) 39 2 28 9
 Mean (SD) glucocorticoid dose at Month 6 (mg/day) 7.8 (5.8) 3.3 (2.9) 7.6 (5.7) 10.1 (6.1)




In patients reported to have arthritis manifestations at base-
line (n = 36), a clinical response of ≥20, ≥50, and ≥80% 
improvement in SLE disease severity following 6  months 
of belimumab therapy was reported in 88.9, 69.4, and 
36.1% of patients, respectively. Improvements in other SLE 
clinical manifestations were also observed from baseline 
to Month 6 (Table 5); however, it is important to note that 
patient numbers were low in some groups.
SLE disease activity assessment
Among patients with assessments at both baseline and 
Month 6, mean PhGA score improved by 18.4 (n = 11) 
and mean SLEDAI-2K score improved by 2.6 (n = 16) 
(Table 6). Among patients with assessments at both base-
line and Month 6 (n = 22), mean PtGA score improved by 
0.5 over 6 months.
Healthcare resource utilization
Over the 6  months prior to belimumab initiation, two 
patients (3.8%) were hospitalized a mean of 2.5 times, 
for a mean duration of 8.0  days; one patient had moder-
ate SLE and the other had severe SLE. Only one (1.9%) 
patient visited the emergency room in the 6 months prior 
to belimumab initiation. Hospitalizations remained infre-
quent during the belimumab treatment period: one patient 
with severe SLE had five admissions to hospital during 
the first 6 months on belimumab, with a total duration of 
49 days. Six (11.5%) patients had an unscheduled visit to 
their rheumatologist, likely for disease management, during 
the 6 months prior to belimumab initiation; incidence of 
unscheduled visits was similar during belimumab treatment 
[5 (9.6%) patients].
Adverse events
AEs were reported in 12 patients (17 AEs in total); those 
that occurred in ≥1 patient were sinusitis/sinus infection 
(n = 3), diarrhea (n = 2), and cephalalgia (n = 2).
Discussion
This was a non-interventional, observational retrospec-
tive medical chart review study executed in Canada. 
This study was commissioned to examine adult patients 
with SLE, receiving belimumab, in real-world clinical 
practice settings. The primary objective was to describe 
overall patterns of SLE care in adult patients with SLE 





























































































































































































































































































































































































































period, and to examine clinical status and outcomes, 
including glucocorticoid use.
The patient population in this real-world setting were 
similar to those seen in the belimumab clinical trial pro-
gram in terms of manifestations, with musculoskeletal, 
mucocutaneous, and immunology being the most com-
mon clinical manifestations [10, 11]. In this real-world 
population, 42.3% of patients had elevated anti-dsDNA 
antibody levels at baseline. In the BLISS-52 and BLISS-
76 trials, patients were required to be positive for anti-
nuclear antibodies (ANA) or anti-dsDNA to participate. 
The proportions of patients with anti-dsDNA ≥30 IU/ml 
were slightly higher in these trials (63–77% across treat-
ment groups) compared with the population in the pre-
sent study [10, 11].
Prolonged use of high-dose glucocorticoids in SLE can 
cause long-term organ damage and morbidity and therefore, 
glucocorticoid reduction is an important factor in treatment 
of SLE [13]. In this study, we observed a decrease in glu-
cocorticoid use following 6 months of belimumab therapy, 
with 59.4% of patients reducing their daily glucocorticoid 
dose and 11.4% of patients discontinuing glucocorticoid 
use. It should also be noted that the proportion of patients 
receiving glucocorticoids decreased from 96.2 to 84.6% 
between 6  months prior to baseline and baseline. Reduc-
tions in glucocorticoid dosage following 6 months of ther-
apy with belimumab were more pronounced in the high 
glucocorticoid group (>7.5  mg/day; −8.2  mg/day) com-
pared with all patients (−5.8 mg/day). Similar results were 
seen in the OBSErve US study, in which 9% of patients dis-
continued glucocorticoids and 77% received a lower dose 
at Month 6. In the OBSErve US study, the percentage of 
patients prescribed glucocorticoids, and the dose received, 
continued to decrease from Month 6 to Month 24 [12].
Regular assessment of disease activity in SLE is vital 
for effective treatment management, as well as to prevent 
the long-term consequences of persistent disease activity 
(e.g., organ damage, mortality, high-dose glucocorticoid 
use). Although both the American College of Rheumatol-
ogy and the European League Against Rheumatism guide-
lines recommend regular monitoring of disease activity in 
patients with SLE [14, 15], there is no standard disease 
assessment tool for SLE recommended by rheumatology 
professional organizations. The present study found that 
the clinical assessment instruments most frequently used by 
physicians treating patients receiving belimumab in Canada 
were the PtGA and PhGA [used by 4/7 (57.1%) physicians 
each] and SLEDAI-2K, BILAG, and patient-reported out-
comes on fatigue using the Fatigue Severity Scale [used by 
2/7 (28.6%) physicians each]. Consistent with the findings 
of OBSErve US, which showed that 50% of physicians did 
not use any disease assessment tool [13], in this study we 
found that no formal disease assessment tool was utilized 
for 42.3% of study patients. This highlights a key care gap 
in the treatment of patients with SLE.
It is imperative that disease activity be measured, ide-
ally with standardized and validated tools, prior to initia-
tion of SLE treatments to adequately assess disease pro-
gression and patient response. The lack of use of current 
disease activity assessment instruments suggests an urgent 
need for Canadian guidelines on the assessment of patients 
with lupus. Rheumatologists managing other rheumatic 
diseases, such as rheumatoid arthritis and psoriatic arthri-
tis, utilize standardized and validated disease activity tools 
Table 6  SLE disease activity scores at baseline and Month 6
PhGA physician global assessment, PtGA patient global assessment, SD standard deviation, SELENA-SLEDAI Safety of Estrogens in Lupus 
Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index, SLE systemic lupus erythematosus
a SLEDAI-2K and its derivations including SELENA-SLEDAI
Total patients with 
SLE (n = 52)
SLE disease severity at baseline
Mild (n = 3) Moderate (n = 40) Severe (n = 9)
PtGA
 Total patients with score at baseline and Month 6 (n) 22 3 15 4
 Mean (SD) score at baseline 60.5 (22.6) 46.7 (10.1) 61.4 (23.0) 67.3 (28.2)
 Mean (SD) improvement from baseline to Month 6 0.5 (24.0) 0.7 (17.1) 2.6 (26.6) −7.5 (20.4)
PhGA
 Total patients with score at baseline and Month 6 (n) 11 3 7 1
 Mean (SD) score at baseline 39.1 (24.4) 10.3 (17.9) 49.0 (17.6) 56.0 (0.0)
 Mean (SD) improvement from baseline to Month 6 18.4 (15.9) 8.3 (14.4) 26.3 (11.0) −7.0 (0.0)
SLEDAI-2Ka
 Total patients with score at baseline and Month 6 (n) 16 3 10 3
 Mean (SD) score at baseline 8.1 (3.2) 4.0 (0.0) 8.4 (2.8) 11.3 (1.2)
 Mean (SD) improvement from baseline to Month 6 2.6 (5.3) 0.0 (0.0) 3.0 (3.3) 4.0 (12.2)
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(physician-derived and patient-reported outcomes) when 
submitting applications for biologic treatment approval 
and renewal. Consistent with these other biologics, many 
medical insurance companies require patients with SLE to 
have SLEDAI-2K ≥6 with positive serology (e.g., ANA, 
anti-dsDNA antibodies, anti-Smith antibodies, low comple-
ment) to qualify for treatment with belimumab. This could 
suggest that rheumatologists managing patients with lupus 
may be required in the future to use validated instruments 
for the management of patients in their clinic.
Given the absence of a standard disease assessment 
tool for SLE recommended by rheumatology professional 
organizations, the overall clinical response improve-
ment was physician-assessed. We observed that treatment 
for 6  months with belimumab led to clinically significant 
improvements, as measured by physicians’ overall assess-
ment, and the reduction or discontinuation of glucocorti-
coids. Over 80% of patients experienced a ≥20% improve-
ment in physician-assessed disease severity and almost 60% 
experienced a ≥50% improvement in physician-assessed 
disease severity. Less than 2% of patients experienced no 
change in symptoms and no patients were reported by their 
physicians to have worsened. These results are comparable 
to those from the OBSErve US study, in which 88.4 and 
48.7% of patients achieved ≥20 and ≥50% improvement in 
overall clinical response following 6 months of belimumab 
therapy [12]. Hospitalizations and unscheduled visits to a 
rheumatologist were similar and infrequent both prior to, 
and during, belimumab treatment.
Observational studies enable data collection from a 
population of patients that provide a more realistic reflec-
tion of real-world clinical practice vs. the strictly controlled 
patient populations included in clinical trials. In this retro-
spective chart review study, a major limitation was that the 
quantification of clinical response (primary outcome) was 
a non-standardized, subjective tool that has not been vali-
dated. The lack of a control group and no randomization to 
treatment risks bias in efficacy measurement. Nevertheless, 
the data show that >70% of patients were able to decrease 
or stop glucocorticoids, which is a quantitative endpoint, 
suggesting the effectiveness and tolerability of belimumab. 
However, the primary aim of this study was not to deter-
mine efficacy, but to establish real-world insights into the 
use of belimumab in clinical practice.
The requirement of at least 6  months of treatment (for 
8 doses) strongly biases this study population in favor of 
those who responded to and tolerated belimumab treat-
ment, or were treated by physicians who were compliant 
with regular patient follow-up. This may limit comparisons 
with other studies of belimumab use in real-world patients 
with SLE. Furthermore, the majority of the patients were 
Caucasian (65.4%), followed by of African origin (15.4%) 
and this may limit the generalizability of our results. Due 
to the number of physicians and patients participating in 
this study and the availability of data, some of the analy-
ses were conducted with low patient numbers (e.g., the 
physician-determined improvement in SLE clinical mani-
festations from baseline to 6 months) and therefore should 
be interpreted with caution. Other limitations include that 
patients were included in the study based on the physician’s 
judgment of a diagnosis of SLE, and that information col-
lected on the patient CRF and PPPF included only best esti-
mates of the current SLE-treated patients and subgroups 
and did not equate with a complete, detailed examination 
and analysis of all actual records for patients with SLE at 
each physician’s site/practice. In addition, the CRFs are an 
interpretation of what was written on the patient charts and 
under-reporting may have occurred if not all events were 
recorded on the patient charts. Physicians had varying lev-
els of experience with validated assessment instruments 
for SLE disease activity, and causal inference of any effect 
of belimumab cannot be made as the study population did 
not include a control arm. In this study, the majority of the 
patients were Caucasian (65.4%) followed by African ori-
gin (15.4%) and therefore this imposes limitation on the 
generalizability of our results.
This uncontrolled retrospective chart review supports 
the results of previous clinical trials in a real-world setting. 
Key findings included the reduction or discontinuation of 
glucocorticoids, which has important clinical implications 
given the adverse effects of long-term use of this therapy, 
and the suggestion of clinically significant improvement as 
measured by physicians’ overall assessment and SLEDAI-
2K scores. The high number of patients with no formal dis-
ease activity assessments highlights a key care gap in the 
treatment of SLE in the real-world setting.
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